The global proton therapy market size valued at USD 454.14 million in 2021 and expected to reach USD 1,084.90 million by 2028 at a CAGR of 11.5% during the forecast period 2022-2028. Proton therapy is also known as proton beam radiation therapy. Proton is a positively charged particle, and in high energy levels protons can destroy the cancer cells. Proton therapy is a non-invasive procedure in which proton radiation used to treat cancer. Proton therapy is a type of external beam radiation therapy, that painlessly delivers radiation through the skin from outside of the body. For the treatment of cancer, proton therapy may be prescribed alone or along with the other treatments such as surgery, chemotherapy, general radiation therapy and or immunotherapy. The global proton therapy market is expected to grow at significant CAGR rates during the forecast period owing to the factors such as growing prevalence of cancer and adaptation of non-invasive techniques such as radiation therapy to treat the cancer tumors. For instance, in September 2017, Elekta and Ion Beam Applications (IBA) has entered into a collaboration to work closely together in software development as well as sales and marketing of each other products. Under the agreement, Companies seeks to develop a novel functionality for the proton therapy treatment in Monaco treatment planning system of Elekta and MOSAIQ oncology information system.
Recent Market Developments:
In February 2020, Ion Beam Applications S.A. signed a contract to install a ProteusONE compact proton therapy solution at the RSPAD Gatot Soebroto Presidential Hospital in Jakarta, Indonesia.
In September 2017, Mevion Medical Systems announced the submission of 510 (K) premarket notifications to U.S. Food and Drug Administration for its proton therapy system MEVION S250i with pencil beam hyper scan technology.